Skip to content
MarketScale
‹ Back to IndustriesSciences

Tips for Treasure Hunting with Nat Geo’s Tim Saylor: Discover the Truth

On each episode of National Geographic’s Diggers, metal detector hobbyists Tim “The Ringmaster” Saylor and his friend “King George” Wyant traverse the United States in search of buried treasure. But treasure means different things to different people, said Saylor, who sat down with host Sean Heath for this episode of Discover the Truth by…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sean Heath · AmateurDiscover the TruthGarrett Metal DetectorsHobby
Share

Key takeaways

01

On each episode of National Geographic’s Diggers, metal detector hobbyists Tim “The Ringmaster” Saylor and his friend “King George” Wyant traverse the United States in search of buried treasure.

02

But treasure means different things to different people, said Saylor, who sat down with host Sean Heath for this episode of Discover the Truth by…

On each episode of National Geographic’s Diggers, metal detector hobbyists Tim “The Ringmaster” Saylor and his friend “King George” Wyant traverse the United States in search of buried treasure. But treasure means different things to different people, said Saylor, who sat down with host Sean Heath for this episode of Discover the Truth by Garrett Metal Detectors.

“I’m one of the very few lucky ones that make a living off this, but I don’t make a living off the things I find,” he said. “I would be doing this whether or not I was on television because I do it for the love of it. This is about the thrill of the hunt and the sport of hunting.”

But learning a sport takes time, Saylor advised.

“Don’t be intimidated. Do what you want and you’ll get alot out of the sport,” he said.

While Garrett has a range of products that vary from nearly “plug and play” models that make it easy for novices to get started in the sport, veteran detectors find more as they become more acquainted with the features and technology.

“We know our machines forwards and backwards. We can sense what’s going on just by what we’re hearing,” Saylor said. “But there’s so much garbage in the ground that you have to learn how to interpret each little tweak to know what’s bad, what’s good, and what’s iffy.”

Among Saylor’s favorite finds are an 22k solid gold mourning ring dated 1744 with an amethyst stone (the “greatest ring I’ve ever found in my life”, according to him).

For the latest news, videos, and podcasts in B2B, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

SH
Sean Heath

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SH
Sean Heath

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512